ホームページ Apoptosis Bcl-2 inhibitor - Autophagy activator - Mitophagy activator - Apoptosis related activator ABT-737 For research use only.

ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.

ABT-737化学構造

CAS No. 852808-04-9

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 29500 国内在庫あり
JPY 25000 国内在庫あり
JPY 85500 国内在庫あり
JPY 445500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール：[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例（371）

製品安全説明書

現在のバッチを見る： 純度： 99.98%
99.98

ABT-737関連製品

シグナル伝達経路

Bcl-2 Signaling Pathways

Bcl-2シグナル伝達経路

Bcl-2阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
DMS53 Function assay 5 to 10 uM 12 hrs Inhibition of BCl-2/Bax interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method 26982372
DMS53 Apoptosis assay 5 to 10 uM 12 hrs Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as caspase-3 cleavage at 5 to 10 uM after 12 hrs by immunoblotting method 26982372
DMS53 Apoptosis assay 5 to 10 uM 12 hrs Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as PARP cleavage at 5 to 10 uM after 12 hrs by immunoblotting method 26982372
DMS53 Function assay 5 to 10 uM 12 hrs Inhibition of BCl-2/Bim interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method 26982372
DMS53 Apoptosis assay 5 to 10 uM 12 hrs Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as cytochrome c release at 5 to 10 uM after 12 hrs by immunoblotting method 26982372
RS4:11 Apoptosis assay 10 uM 24 hrs Induction of apoptosis in human RS4:11 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method 23047228
IM9 Apoptosis assay 10 uM 24 hrs Induction of apoptosis in human IM9 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method 23047228
BP3 Apoptosis assay 10 uM 24 hrs Induction of apoptosis in human BP3 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method 23047228
MDA-MB-231 Function assay 0.03 to 1 uM 1 hr Antagonist activity at recombinant Bcl-XL assessed as restoration of BIM BH3-induced cytochrome c release in mitochondria isolated from MDA-MB-231 cells at 0.03 to 1 uM after 1 hr by Western blot analysis 22747598
MDA-MB-231 Function assay 0.03 to 1 uM 1 hr Antagonist activity at recombinant Bcl-XL assessed as restoration of BIM BH3-induced Smac protein release in mitochondria isolated from MDA-MB-231 cells at 0.03 to 1 uM after 1 hr by Western blot analysis 22747598
HeLa Function assay 10 uM 16 hrs Inhibition of Rluc-Bax/eYFP-Bcl-xL interaction expressed in human HeLa cells at 10 uM after 16 hrs by BRET assay 22425031
HeLa Function assay 1 uM 12 hrs Induction of Bcl-xL-mediated apoptosis in doxycyclin-stimulated human HeLa cells overexpressing Noxa at 1 uM after 12 hrs by Hoechst staining 22386982
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y101H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.38 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 F97V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.3 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.29 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.27 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 V141A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.19 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 R100E mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.16 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.073 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 delta136T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.06 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.058 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.021 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142Gdelta136T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.01 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E96G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0058 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E129H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0045 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Wild type Bcl-2-like protein 1 expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0034 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y195F mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0015 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A93V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.0014 μM. 21807512
BL21 Function assay 10 uM 3 hrs Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 G196A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay, Ki = 0.001 μM. 21807512
RS4;11 Function Assay 100 nM 1/3/6 h induces caspase-dependent Mcl-1 cleavage 24951472
OPM-2  Apoptosis Assay 125/250/500 nM 48h  induces cell apoptosis in a dose-dependent manner 25008202
COG-LL-319 Function Assay 100 nM 1/3/6 h induces caspase-dependent Mcl-1 cleavage 24951472
RPMI-8226  Apoptosis Assay 125/250/500 nM 48h  induces cell apoptosis in a dose-dependent manner 25008202
OPM-2  Cell Viability Assay 125/250/500 nM 48h  decreases cell viability in a dose-dependent manner 25008202
RPMI-8226  Cell Viability Assay 125/250/500 nM 48h  decreases cell viability in a dose-dependent manner 25008202
Caco2 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
Colo205 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
SW480 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
HT29 Apoptosis Assay 1/5/10 μM 48 h causes cell death in a dose-dependent manner 25192188
CX-1 Growth Inhibition Assay 0.2–60 μM 72 h IC50=1.8 μM 25208882
LS174T Growth Inhibition Assay 0.2–60 μM 72 h IC50=18.3 μM 25208882
Clone A Growth Inhibition Assay 0.2–60 μM 72 h IC50=7.5 μM 25208882
MM.1S Function Assay 500/750 nM 24/48 h downregulates Bim, principally the EL isoform 25208888
U266 Function Assay 500/750 nM 24/48 h downregulates Bim, principally the EL isoform 25208888
RPMI8226 Function Assay 500/750 nM 24/48 h downregulates Bim, principally the EL isoform 25208888
A5-RT3 Function Assay 5 μM 6 h induces the release of mitochondrial proteins and reduces clonogenic survival in a caspase-independent manner 25210795
HaCaT Function Assay 10 μM 24/48 h induces MMP and DNA fragmentation 25210795
A5-RT3 Function Assay 10 μM 24/48 h induces MMP and DNA fragmentation 25210795
HaCaT Cell Viability Assay 0.1/1/10 μM 24 h decreases cell viability in a dose-dependent manner 25210795
A5-RT3 Cell Viability Assay 0.1/1/10 μM 24 h decreases cell viability in a dose-dependent manner 25210795
HCT116 Cell Viability Assay 0-10 μM 24 h  IC50=20.49 µM 25304383
LS411N Cell Viability Assay 0-10 μM 24 h  IC50=11.47 µM 25304383
SW620 Cell Viability Assay 0-10 μM 24 h  IC50=12.24 µM 25304383
Caco-2 Cell Viability Assay 0-10 μM 24 h  IC50=19.7 µM 25304383
DLD1 Cell Viability Assay 0-10 μM 24 h  IC50=18.78 µM 25304383
RL  Cell Viability Assay 0.0001-1 μM 96 h decreases the cell viability in a dose-dependent manner 25373508
RKO Cell Viability Assay 0-10 μM 24 h  IC50> 25 µM 25304383
OcI-LY18 Cell Viability Assay 0.0001-1 μM 96 h decreases the cell viability in a dose-dependent manner 25373508
H1299 Apoptosis Assay 20 μM 48 h induces apoptosis significantly combined with aspirin 25388762
Sc-1 Cell Viability Assay 0.0001-1 μM 96 h decreases the cell viability in a dose-dependent manner 25373508
A549 Apoptosis Assay 20 μM 48 h induces apoptosis significantly combined with aspirin 25388762
HT-29 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
HCT-116 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
HO-8910 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
H1299 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
ZR-75-1  Function Assay 5 μM 24 h enhances thelevel of Mcl-1 expression  25409124
A549 Cell Viability Assay 0-20 μM 72 h decreases the cell survival in a dose-dependent manner combined with aspirin 25388762
MCF-7 Function Assay 5 μM 24 h enhances thelevel of Mcl-1 expression  25409124
MDA-MB 231  Function Assay 5 μM 24 h enhances thelevel of Mcl-1 expression  25409124
MCF-7 Apoptosis Assay 5 μM 4/24/48 h increases the cleaved PARP 25409124
MCF-7 Cell Viability Assay 5 μM 48 h enhances the sensitivity to or radiation 25409124
K562 Cell Viability Assay 1-10 μM 48 h IC50=26.7 μM 25596561
U87 Function Assay 50 μM 24 h reduces the mRNA expression levels of MMP-2, MMP-14 and Bcl-2 25667663
HL-60 AAA-Bcl-2 Apoptosis Assay 0-5 μM 48 h IC50=0.87 μm，induces cell apoptosis in a dose-dependent manner 25711460
HL-60 EEE-Bcl-2 Apoptosis Assay 0-5 μM 48 h IC50=5 μm， induces cell apoptosis in a dose-dependent manner 25711460
U937  Apoptosis Assay 0.5 μM 24 h enhances cleavage of PARP and caspase-3 as well as Noxa level 25714024
U937 Apoptosis Assay 0.125-2 μM 24 h enhances DHA/X-11-induced apoptosis 25714024
HCT116 BAX BAK1 DKO Autophagy Assay 10 μM 12 h  induces a complete autophagic response 25715028
HCT116 BAX BAK1 DKO Function Assay 10 μM 12 h  increases GFP-LC3B puncta 25715028
HCT116 Autophagy Assay 10 μM 12 h  induces a complete autophagic response 25715028
HCT116 Function Assay 10 μM 12 h  increases GFP-LC3B puncta 25715028
HCT116 BAX BAK1 DKO Function Assay 3/10 μM 12 h  induces a dose-dependent increase in LC3B-II conversion and SQSTM1 degradation 25715028
HCT116 Function Assay 3/10 μM 12 h  induces a dose-dependent increase in LC3B-II conversion and SQSTM1 degradation 25715028
MM.1s Apoptosis Assay 0-1.6 μM 24 h induces cell apoptosis 25893290
MWCL-1 Apoptosis Assay 0-1.6 μM 24 h induces cell apoptosis 25893290
BCWM.1 Apoptosis Assay 0-1.6 μM 24 h induces cell apoptosis 25893290
B16 Cell Viability Assay 100 nM 72 h enhances curcumin-induced anti-survival  26116776
WM-115 Cell Viability Assay 100 nM 72 h enhances curcumin-induced anti-survival  26116776
LOUCY Growth Inhibition Assay 100-1000 nM 48 h IC50=32.8±10.9 nM 26172269
JURKAT Growth Inhibition Assay 100-1000 nM 48 h IC50=955±9.3 nM 26172269
CEM S Apoptosis Assay 10-1000 nM 24 h causes the cleavage of Bcl-2 and the downregulation of Bcl-xL and Mcl-1 26392332
MOLT-4 Apoptosis Assay 10-1000 nM 24 h causes the cleavage of Bcl-2 and the downregulation of Bcl-xL and Mcl-1 26392332
CEM S Growth Inhibition Assay 10-5000 nM 72 h IC50=12.1 μM 26392332
CEM R Growth Inhibition Assay 10-5000 nM 72 h IC50=5.4 μM 26392332
JURKAT Growth Inhibition Assay 10-5000 nM 72 h IC50=66 μM 26392332
RS4;11 Growth Inhibition Assay 10-5000 nM 72 h IC50=0.002 μM 26392332
MOLT-4 Growth Inhibition Assay 10-5000 nM 72 h IC50=0.198 μM 26392332
MC-3  Apoptosis Assay 5/10/20 μM 24 h induces caspase-mediated apoptosis 26447615
HN22  Apoptosis Assay 2.5/7.5/22.5 μM 24 h induces caspase-mediated apoptosis 26447615
HN22  Growth Inhibition Assay 2.5/7.5/22.5 μM 24 h inhibits cell growth in a dose-dependent manner 26447615
MC-3  Growth Inhibition Assay 5/10/20 μM 24 h inhibits cell growth in a dose-dependent manner 26447615
Kasumi-1 Apoptosis Assay 0-10 μM 24 h induces cell apoptosis in a dose-dependent manner 26552712
KG1a Apoptosis Assay 0-10 μM 24 h induces cell apoptosis in a dose-dependent manner 26552712
Kasumi-1 Cell Viability Assay 0-10 μM 24 h IC50=4.87 μM, decreases cell viability in a dose-dependent manner 26552712
KG1a Cell Viability Assay 0-10 μM 24 h IC50=7.68 μM, decreases cell viability in a dose-dependent manner 26552712
OCI-Ly1  Cell Viability Assay 250 nM  72 h caused 97% loss of viability in cells transfected with BCL6 siRNA 26657288
Eu-Myc Apoptosis assay 1 uM Induction of apoptosis in mouse Eu-Myc cells overexpressing BCL2 assessed as inhibition of colony formation at 1 uM 18040043
KB Cytotoxicity assay 0.5 uM Cytotoxicity in human siRNA-mediated-MCL1-kncok down KB cells overexpressing BCL2 at 0.5 uM 18040043
HCT116 Apoptosis assay 48 hrs Induction of apoptosis in human HCT116 p53+/+ cells after 48 hrs by Annexin V-FITC staining-based flow cytometric method 26982372
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 8X His-tagged human Bcl-xL expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, Ki = 0.001 μM. 22448988
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, Ki = 0.0006 μM. 22448988
Remb1 Cytotoxicity assay 24 hrs Cytotoxicity against human Remb1 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 1.4 μM. 29453135
RS4:11 Cytotoxicity assay 24 hrs Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 0.33 μM. 29453135
SKOV3 Growth inhibition assay 72 hrs Growth inhibition of human SKOV3 cells after 72 hrs by MTT assay, IC50 = 46.59 μM. 27712939
U266 Growth inhibition assay 72 hrs Growth inhibition of human U266 cells after 72 hrs by MTT assay, IC50 = 27.35 μM. 27712939
MCF7 Growth inhibition assay 72 hrs Growth inhibition of human MCF7 cells after 72 hrs by MTT assay, IC50 = 25.33 μM. 27712939
HL60 Growth inhibition assay 72 hrs Growth inhibition of human HL60 cells after 72 hrs by MTT assay, IC50 = 0.97 μM. 27712939
NCI-H1417 Cytotoxicity assay 4 days Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay, IC50 = 0.1734 μM. 23448298
NCI-H187 Cytotoxicity assay 4 days Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay, IC50 = 0.1377 μM. 23448298
NCI-H1963 Cytotoxicity assay 4 days Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay, IC50 = 0.054 μM. 23448298
K562 Apoptosis assay 48 hrs Induction of apoptosis in Mcl1 dependent human K562 cells after 48 hrs by Annexin V staining based flow cytometry, IC50 = 16.4 μM. 23314054
RS4:11 Apoptosis assay 48 hrs Induction of apoptosis in Bcl2 dependent human RS4:11 cells after 48 hrs by Annexin V staining based flow cytometry, IC50 = 0.27 μM. 23314054
NCI-H1417 Antiproliferative assay 4 days Antiproliferative activity against human NCI-H1417 cells after 4 days by WST8 assay, IC50 = 0.412 μM. 22747598
NCI-H1963 Antiproliferative assay 4 days Antiproliferative activity against human NCI-H1963 cells after 4 days by WST8 assay, IC50 = 0.059 μM. 22747598
NCI-H146 Antiproliferative assay 4 days Antiproliferative activity against human NCI-H146 cells after 4 days by WST8 assay, IC50 = 0.037 μM. 22747598
K562 Cytotoxicity assay 48 hrs Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 34.7 μM. 22582991
HL60 Cytotoxicity assay 48 hrs Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 0.76 μM. 22582991
CCRF-CEM Cytotoxicity assay 48 hrs Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 0.74 μM. 22582991
NCI-H1417 Growth inhibition assay 4 days Growth inhibition of human NCI-H1417 cells after 4 days by WST8 assay, IC50 = 0.13 μM. 22448988
NCI-H146 Growth inhibition assay 4 days Growth inhibition of human NCI-H146 cells after 4 days by WST8 assay, IC50 = 0.097 μM. 22448988
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 8X His-tagged human Bcl-xL expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, IC50 = 0.006 μM. 22448988
BL21 (DE3) Function assay 2 hrs Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay, IC50 = 0.002 μM. 22448988
HCT116 Cytotoxicity assay 72 hrs Cytotoxicity against human HCT116 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay, IC50 = 47.7 μM. 22172701
DU145 Cytotoxicity assay 48 hrs Cytotoxicity against human DU145 cells after 48 hrs by cell titer-blue assay, IC50 = 27.6 μM. 19743858
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs by cell titer-blue assay, IC50 = 21.26 μM. 19743858
Hepa-1c1c7 Cytotoxicity assay 48 hrs Cytotoxicity against mouse Hepa-1c1c7 cells after 48 hrs by cell titer-blue assay, IC50 = 8.68 μM. 19743858
H460 Cytotoxicity assay 48 hrs Cytotoxicity against human H460 cells after 48 hrs by cell titer-blue assay, IC50 = 8.03 μM. 19743858
SU-8686 Cytotoxicity assay 48 hrs Cytotoxicity against human SU-8686 cells after 48 hrs by cell titer-blue assay, IC50 = 4.24 μM. 19743858
HCT116 Cytotoxicity assay 48 hrs Cytotoxicity against human HCT116 cells after 48 hrs by cell titer-blue assay, IC50 = 4.06 μM. 19743858
Jurkat Cytotoxicity assay 48 hrs Cytotoxicity against human Jurkat cells after 48 hrs by cell titer-blue assay, IC50 = 1.38 μM. 19743858
MEF Cytotoxicity assay 24 hrs Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum, EC50 = 0.051 μM. 21366295
MEF Cytotoxicity assay 24 hrs Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% serum, EC50 = 0.051 μM. 21366295
MEF Cytotoxicity assay 24 hrs Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 1% serum, EC50 = 0.00203 μM. 21366295
NCI-H146 Cytotoxicity assay 48 hrs Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum, EC50 = 0.087 μM. 18841882
FL5.12 Cytotoxicity assay 24 hrs Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum, EC50 = 0.03 μM. 18841882
FL5.12 Cytotoxicity assay 24 hrs Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum, EC50 = 0.0077 μM. 18841882
UPCI:SCC90 Growth Inhibition Assay 72 h GI50=6.6 ± 1.5 μM 25139387
UD-SCC2 Growth Inhibition Assay 72 h GI50=28 ± 2.9 μM 25139387
93-VU-147T Growth Inhibition Assay 72 h GI50=4.3 ± 3.5 μM 25139387
UM-SCC47 Growth Inhibition Assay 72 h GI50=19 ± 12.3 μM 25139387
UM-SCC22B Growth Inhibition Assay 72 h GI50=19 ± 2.9 μM 25139387
PCI-15B Growth Inhibition Assay 72 h GI50=11 ± 4.5 μM 25139387
PCI-13 Growth Inhibition Assay 72 h GI50=15 ± 1.8 μM 25139387
OCI-AML3 Growth Inhibition Assay 72 h IC50 = 1950 nM 26045609
MOLM-13  Growth Inhibition Assay 72 h IC50 = 27.9 nM 26045609
HL-60  Growth Inhibition Assay 72 h IC50 = 10.7 nM 26045609
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
Toledo Apoptosis assay Induction of apoptosis in human Toledo cells, LD50 = 0.06 μM. 24900652
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139
MOLT4 Antiproliferative assay Antiproliferative activity against human MOLT4 cells in presence of 10% human serum, EC50 = 0.622 μM. 28926247
RS4:11 Antiproliferative assay Antiproliferative activity against human RS4:11 cells in presence of 10% human serum, EC50 = 0.024 μM. 28926247
CLL Apoptosis assay Induction of apoptosis in human CLL cells, EC50 = 0.0045 μM. 20925433
SUDHL4 Growth inhibition assay Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 10% HS, EC50 = 0.85 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of 3% FBS, EC50 = 0.22 μM. 17256834
SUDHL4 Growth inhibition assay Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 3% FBS, EC50 = 0.22 μM. 17256834
RS11380 Growth inhibition assay Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 10% HS, EC50 = 0.15 μM. 17256834
DoHH2 Growth inhibition assay Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 10% HS, EC50 = 0.13 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of 3% FBS, EC50 = 0.05 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of bovine gelatin, EC50 = 0.03 μM. 17256834
DoHH2 Growth inhibition assay Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 3% FBS, EC50 = 0.0083 μM. 17256834
RS11380 Growth inhibition assay Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 3% FBS, EC50 = 0.014 μM. 17256834
FL5.12 Function assay Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of bovine gelatin, EC50 = 0.008 μM. 17256834
U266 Growth Inhibition Assay IC50=0.68 μM 25535900
NCI-H929 Growth Inhibition Assay IC50=15.21 μM 25535900
MM.1S Growth Inhibition Assay IC50=0.40 μM 25535900
RPMI 8226 Growth Inhibition Assay IC50=0.25 μM 25535900
U937 Growth Inhibition Assay IC50=5.29 μM 25535900
C1498 Growth Inhibition Assay IC50=6.13 μM 25535900
THP-1 Growth Inhibition Assay IC50=1.27 μM 25535900
Kasumi-1 Growth Inhibition Assay IC50=0.01 μM 25535900
Kasumi-1/ABT Growth Inhibition Assay IC50=0.51 μM 25535900
JurkatΔBak Growth Inhibition Assay IC50>50 μM 25535900
HL60/VCR Growth Inhibition Assay IC50>100 μM 25535900
K562/Bcl- 2-IRESBim Growth Inhibition Assay IC50=0.35 μM 25535900
Jurkat Growth Inhibition Assay IC50=0.66 μM 25535900
K562/Mcl -1-IRESBim Growth Inhibition Assay IC50=9.3 μM 25535900
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells 29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
特性 First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)		 Bcl-xL [1]
(Cell-free assay)		 Bcl-w [1]
(Cell-free assay)		 Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In Vitro
In vitro ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]
Kinase Assay Fluorescence polarization assays
Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
細胞実験 細胞株 SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
濃度 0.001-10 μM
反応時間 48 hours
実験の流れ

SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.
実験結果図 Methods Biomarkers 結果図 PMID
Western blot PARP / c-PARP / cleaved caspase 3 Hif-1a γ-H2AX / p-ATM 21393866
Immunofluorescence cytochrome C Bax Bim AIF p65 26447615
Growth inhibition assay Cell viability 22311987
ELISA IL-6 / IL-8 21084274
In Vivo
In Vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]
動物実験 動物モデル Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
投与量 20 and 30 mg/kg
投与経路 For intraperitoneal (i.p.) every day

化学情報

分子量 813.43 化学式

C42H45ClN6O5S2
CAS No. 852808-04-9 SDF Download ABT-737 SDFをダウンロードする
Smiles CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
保管

In vitro
Batch:

DMSO : 100 mg/mL ( (122.93 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

mg/kg g μL 匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問（FAQ）

質問1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?

回答
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Tags: ABT-737を買う | ABT-737 ic50 | ABT-737供給者 | ABT-737を購入する | ABT-737費用 | ABT-737生産者 | オーダーABT-737 | ABT-737化学構造 | ABT-737分子量 | ABT-737代理店